🇺🇸 FDA
Patent

US 11786603

Optimized transglutaminase site-specific antibody conjugation

granted A61KA61K47/68031A61K47/6883

Quick answer

US patent 11786603 (Optimized transglutaminase site-specific antibody conjugation) held by REGENERON PHARMACEUTICALS, INC. expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
32
CPC classes
A61K, A61K47/68031, A61K47/6883, A61K47/6889, A61P